Zhongyou Kangni

Beijing Zhongyou Kangni Biotechnology is a clinical-stage biopharmaceutical company focused on the development of innovative Natural Killer (NK) cell therapies for cancer treatment. Based in Beijing, the company utilizes its proprietary Universal CAR-NK platform to engineer off-the-shelf cellular immunotherapies designed to overcome the limitations of traditional CAR-T treatments, such as high cost and safety concerns. Their lead candidate, ZYKN-001, is a CAR-NK therapy targeting GPC3 for the treatment of advanced hepatocellular carcinoma. The company's pipeline also includes programs targeting mesothelin and other solid tumor antigens, aiming to provide accessible and effective treatments for patients with refractory malignancies. Zhongyou Kangni is positioned as a specialist in the expansion and genetic modification of allogeneic NK cells for large-scale clinical application.